Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.
If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com
For other Takeda news releases, please visit the Takeda.com Newsroom.
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline
Takeda China announces ADCETRIS® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas
